Pharmaceuticals Ingredients Cyproheptadine CAS No 86386-73-4 Mebendazole Fluconazole

• Varieties: Parasite Disease Prevention Medicine
• Component: Animal
• Type: The First Class
• Pharmacodynamic Influential Factors: Animal Species
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 09853
• Model NO.: fluconazole
• Product: Fluconazole
• Mf: C13h12f2n6o
• CAS: 86386-73-4
• Transport Package: Drum
• Specification: 99%
• Trademark: HS
• Origin: China
• HS Code: 2904201000
• Production Capacity: 100000

Product Description

Fluconazole
CAS No.: 86386-73-4
MF: C13H12F2N6O
MW: 306.27
EINECS: 200-659-6
Melting point: 138-140°C
Storage temp.: −20°C
Solubility : DMSO: 5 mg/mL
Chemical Properties: White to Off-White Solid
Usage: For the treatment of fungal infections
 

Fluconazole is an antifungal medication that is administered orally or intravenously. It is used to treat a variety of fungal infections, especially Candida infections of the vagina,mouth, throat, and bloodstream. It is also used to prevent infections in people with weak immune systems, including those with neutropenia due to cancer chemotherapy, transplant patients, and premature babies. Its mechanism of action involves interfering with synthesis of the fungal cell membrane.

Fluconazole is a first-generation triazole antifungal medication. It differs from earlier azole antifungals (such as ketoconazole) in that its structure contains a triazole ring instead of an imidazole ring. While the imidazole antifungals are mainly used topically, fluconazole and certain other triazole antifungals are preferred when systemic treatment is required because of their improved safety and predictable absorption when administered orally.

Fluconazole's spectrum of activity includes most Candida species (but not Candida krusei or Candida glabrata), Cryptococcus neoformans, some dimorphic fungi, and dermatophytes, among others. Common uses include:


1)The treatment of non-systemic Candida infections of the vagina,throat, and mouth.

2)Certain systemic Candida infections in people with healthy immune systems, including infections of the bloodstream, kidney, or joints. Other antifungals are usually preferred when the infection is in the heart or central nervous system, and for the treatment of active infections in people with weak immune systems.

3)The prevention of Candida infections in people with weak immune systems, such as those neutropenic due to cancer chemotherapy, those with advanced HIV infections, transplant patients, and premature infants.

4)As a second-line agent for the treatment of cryptococcal meningoencephalitis, a fungal infection of the central nervous system.

 

Items	Standard	Results
Appearance	Off-white or white crystal or crystalline powder	White crystalline powder
Melting point	137-141ºC	140ºC
Identification	(1) (2) should comply with standard (3) should be positive reaction	Complies Complies
Clarity of solution	Should comply with standard	Complies
Assay of fluorine	Should be between 11.1-12.4%	12.3%
Involved substance	Should comply with standard	Complies
Assay of chloride	Should comply with standard	Complies
Loss on drying	Not more than 0.5%	0.2%
Residue in ignition	Not more than 0.1%	0.02%
Heavy metals	Not more than 20ppm	Complies
Limit of microbe	Should comply with standard	Complies
Assay	should not less than 98.5% on dry basis	99.8%